“Everyone always says to me, ‘You’re working on the cure for cancer,’” says Elizabeth C. Ng ’78, a member of the Alumni Association’s board. But cancer isn’t a single target, as she knows all too well. As CEO of Ocean Biomedical, which is working on potential therapies for several types of cancer, she also knows there are many ways to attack it. “If a treatment keeps patients alive long enough for the next innovation to come out, maybe you can call it a cure,” she allows.
Ng’s leadership of Ocean—which also works to advance therapeutic candidates for fibrosis, malaria, and hepatitis B—caps off a career of consulting or working for the largest biotech companies and most of the big pharmaceutical companies. The oldest of five in a family that emigrated from Hong Kong, she grew up in San Francisco with her sights on attending MIT because it was featured in the sci-fi stories she loved. After earning a physics degree, she worked at semiconductor startups and computer companies in Northern California, got an MBA from Stanford, and transitioned into management in the life sciences.
At Ocean, Ng helps bridge the gap between medical research and the clinic. Scientists often lack the resources and know-how to run the human trials needed to get a drug approved. Ocean identifies promising discoveries and creates subsidiaries to license those discoveries and then move them forward into clinical trials. For Ng, that means days spent assessing new research programs, strategizing the best clinical and regulatory paths forward for the current programs, and then implementing those plans, as well as continuing to raise capital to support the scientific and clinical work. If trials succeed, a subsidiary may spin out from the parent company or partner with a biotech or pharmaceutical company to complete development and reach patients.
Don’t settle for half the story.
Get paywall-free access to technology news for the here and now.
